| Home | E-Submission | Sitemap | Contact Us |  
Korean J Med > Volume 87(1); 2014 > Article
The Korean Journal of Medicine 2014;87(1): 9-13.
글루카곤양 펩티드-1 유사체
엄영실, 김병준
가천대학교 길병원 내과
Glucagon-Like Peptide-1 (GLP-1) Agonist
Young Sil Eom, Byung-Joon Kim
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
Corresponding Author: Byung-Joon Kim ,Tel: +82-32-460-8903, Fax: +82-32-469-4320, Email: kbjoon4u@gilhospital.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus. The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.
Keywords: Glucagon-like peptide 1 analogue; Incretin; Type 2 diabetes
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community